Skip to main content
Top
Published in: Current Treatment Options in Neurology 4/2011

01-08-2011 | Neuro-oncology (Neoplasms)

Medical Management of Patients With Brain Tumors

Author: Amy A. Pruitt, MD

Published in: Current Treatment Options in Neurology | Issue 4/2011

Login to get access

Opinion statement

Patients with brain tumors require meticulous attention to medical issues resulting from their disease or its therapy. The following specific issues are the ones most frequently arising in the purview of neurologists: (1) Vasogenic edema: Corticosteroids should be used in divided doses in the minimum amount required to control symptoms and should be tapered as quickly as possible. Some patients may require long-term steroid supplementation, and symptoms of adrenal insufficiency should be investigated with 8 am cortisol measurement and treated with appropriate repletion. (2) Seizures: Patients with brain tumors should receive antiepileptic drugs only if they have had seizures, and the drugs should be chosen to minimize cognitive effects and interactions with concurrently administered chemotherapy. Levetiracetam is an excellent choice for patients with partial seizures and is available both orally and parenterally. Lamotrigine is another reasonable choice but requires slow titration. (3) Venous thromboembolism: All brain tumor patients should receive perioperative venous thrombosis prophylaxis with compression boots and enoxaparin or dalteparin. Lifelong treatment with low molecular weight heparinoids or warfarin is required for those developing venous thromboembolism. (4) Other problems: Long-term survivors of brain tumors should be monitored indefinitely for cognitive problems, endocrine dysfunction, and development of secondary neoplasms. Modafinil can improve mood and attention impairments.
Literature
1.
go back to reference Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncol. 2008;9(9):884–91.PubMedCrossRef Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncol. 2008;9(9):884–91.PubMedCrossRef
2.
go back to reference Wenger NS, Vespa PM. Ethical issues in patient-physician communication about therapy for cancer: professional responsibilities of the oncologist. Oncologist. 2010;15 Suppl 1:43–8.PubMedCrossRef Wenger NS, Vespa PM. Ethical issues in patient-physician communication about therapy for cancer: professional responsibilities of the oncologist. Oncologist. 2010;15 Suppl 1:43–8.PubMedCrossRef
3.
go back to reference Wilson JF. Cancer care: a microcosm of the problems facing all of health care. Ann Intern Med. 2009;150(8):573–6.PubMed Wilson JF. Cancer care: a microcosm of the problems facing all of health care. Ann Intern Med. 2009;150(8):573–6.PubMed
4.
go back to reference Keating NL, Landrum MB, Rogers Jr SO, et al. Physician factors associated with discussions about end-of-life care. Cancer. 2010;116(4):998–1006.PubMedCrossRef Keating NL, Landrum MB, Rogers Jr SO, et al. Physician factors associated with discussions about end-of-life care. Cancer. 2010;116(4):998–1006.PubMedCrossRef
5.••
6.
go back to reference Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006;20(6):1337–61.PubMedCrossRef Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006;20(6):1337–61.PubMedCrossRef
7.
go back to reference Watling CJ, Cairncross JG. Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases. J Neurosurg. 2002;97(1):224–6.PubMedCrossRef Watling CJ, Cairncross JG. Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases. J Neurosurg. 2002;97(1):224–6.PubMedCrossRef
8.
go back to reference Vecht CJ, Hovestadt A, Verbiest HBC, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994;44:675–80.PubMed Vecht CJ, Hovestadt A, Verbiest HBC, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994;44:675–80.PubMed
9.
go back to reference Meyer G, Badenhoop K. Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy. Med Klin (Munich). 2003;98(5):266–70.CrossRef Meyer G, Badenhoop K. Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy. Med Klin (Munich). 2003;98(5):266–70.CrossRef
10.
go back to reference Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111(7):541–5.PubMedCrossRef Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111(7):541–5.PubMedCrossRef
11.
go back to reference Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol. 2003;63(3):263–70.PubMedCrossRef Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol. 2003;63(3):263–70.PubMedCrossRef
12.
go back to reference Kovacs JA, Gill VJ, Meshnick S, et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001;286(19):2450–60.PubMedCrossRef Kovacs JA, Gill VJ, Meshnick S, et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001;286(19):2450–60.PubMedCrossRef
13.
go back to reference Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348(8):727–34.PubMedCrossRef Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348(8):727–34.PubMedCrossRef
14.
go back to reference Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002;287(2):236–40.PubMedCrossRef Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002;287(2):236–40.PubMedCrossRef
15.
go back to reference Wood GJ, Shega JW, Lynch B, et al. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time. .. nothing was working”. JAMA. 2007;298(10):1196–207.PubMedCrossRef Wood GJ, Shega JW, Lynch B, et al. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time. .. nothing was working”. JAMA. 2007;298(10):1196–207.PubMedCrossRef
16.
go back to reference Lee JW, Bromfield EB, Kesari S. Antiemetic properties of the antiepileptic drug levetiracetam. N Engl J Med. 2008;359(17):1853.PubMedCrossRef Lee JW, Bromfield EB, Kesari S. Antiemetic properties of the antiepileptic drug levetiracetam. N Engl J Med. 2008;359(17):1853.PubMedCrossRef
17.
go back to reference Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.PubMed Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.PubMed
18.
go back to reference van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–26.PubMedCrossRef van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–26.PubMedCrossRef
19.
go back to reference Mamon HJ, Wen PY, Burns AC, et al. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia. 1999;40(3):341–4.PubMedCrossRef Mamon HJ, Wen PY, Burns AC, et al. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia. 1999;40(3):341–4.PubMedCrossRef
20.
go back to reference Mattson RH. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis. 2004;1 Suppl 1:S10–7.PubMed Mattson RH. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis. 2004;1 Suppl 1:S10–7.PubMed
21.•
go back to reference Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008; 71(9):665–669.PubMedCrossRef Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008; 71(9):665–669.PubMedCrossRef
22.
go back to reference Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6.PubMedCrossRef Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6.PubMedCrossRef
24.
go back to reference Weiger WA, Smith M, Boon H, et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med. 2002;137(11):889–903.PubMed Weiger WA, Smith M, Boon H, et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med. 2002;137(11):889–903.PubMed
25.
go back to reference Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80(3):313–32.PubMedCrossRef Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80(3):313–32.PubMedCrossRef
26.
27.
go back to reference Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000;89(3):640–6.PubMedCrossRef Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000;89(3):640–6.PubMedCrossRef
28.
go back to reference Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27(29):4865–73.PubMedCrossRef Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27(29):4865–73.PubMedCrossRef
29.
go back to reference Perry JR. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Curr Opin Neurol. 2010;23(6):592–6.PubMedCrossRef Perry JR. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Curr Opin Neurol. 2010;23(6):592–6.PubMedCrossRef
30.
go back to reference Drappatz J, Wong ET, Schiff D, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73(1):222–7.PubMedCrossRef Drappatz J, Wong ET, Schiff D, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73(1):222–7.PubMedCrossRef
31.••
go back to reference Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8(2):221–227.PubMedCrossRef Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8(2):221–227.PubMedCrossRef
32.
go back to reference Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-Oncology. 2008;10(3):355–60.PubMedCrossRef Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-Oncology. 2008;10(3):355–60.PubMedCrossRef
33.
go back to reference Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol. 2009;27(29):4889–94.PubMedCrossRef Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol. 2009;27(29):4889–94.PubMedCrossRef
34.
go back to reference Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–505.PubMedCrossRef Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–505.PubMedCrossRef
35.
go back to reference Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. 2004;5(6):511–7.PubMedCrossRef Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. 2004;5(6):511–7.PubMedCrossRef
36.
go back to reference Cesarone MR, Belcaro G, Nicolaides AN, et al. Venous thrombosis from air travel: the LONFLIT3 study—prevention with aspirin vs. low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology. 2002;53(1):1–6.CrossRef Cesarone MR, Belcaro G, Nicolaides AN, et al. Venous thrombosis from air travel: the LONFLIT3 study—prevention with aspirin vs. low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology. 2002;53(1):1–6.CrossRef
37.••
go back to reference Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8(9):1959–1965.PubMedCrossRef Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8(9):1959–1965.PubMedCrossRef
38.
go back to reference Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis. 1999;8(2):139–42.PubMedCrossRef Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis. 1999;8(2):139–42.PubMedCrossRef
39.
go back to reference Triebel KL, Martin RC, Nabors LB, et al. Medical decision-making capacity in patients with malignant glioma. Neurology. 2009;73(24):2086–92.PubMedCrossRef Triebel KL, Martin RC, Nabors LB, et al. Medical decision-making capacity in patients with malignant glioma. Neurology. 2009;73(24):2086–92.PubMedCrossRef
40.
go back to reference Hickok JT, Roscoe JA, Morrow GR, et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005;104(8):1772–8.PubMedCrossRef Hickok JT, Roscoe JA, Morrow GR, et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005;104(8):1772–8.PubMedCrossRef
41.
go back to reference Pelletier G, Verhoef MJ, Khatri N, et al. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. 2002;57(1):41–9.PubMedCrossRef Pelletier G, Verhoef MJ, Khatri N, et al. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. 2002;57(1):41–9.PubMedCrossRef
42.
go back to reference Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522–7.PubMed Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522–7.PubMed
43.
go back to reference Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.PubMedCrossRef Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.PubMedCrossRef
44.
go back to reference Shaw EG, Rosdhal R, D’Agostino Jr RB, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415–20.PubMedCrossRef Shaw EG, Rosdhal R, D’Agostino Jr RB, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415–20.PubMedCrossRef
45.
go back to reference Pruitt A, Dalmau J, Detre J, et al. Episodic neurologic dysfunction with migraine and reversible imaging findings after radiation. Neurology. 2006;67(4):676–8.PubMedCrossRef Pruitt A, Dalmau J, Detre J, et al. Episodic neurologic dysfunction with migraine and reversible imaging findings after radiation. Neurology. 2006;67(4):676–8.PubMedCrossRef
46.
go back to reference Grimm SA, Yahalom J, Abrey LE, et al. Retinopathy in survivors of primary central nervous system lymphoma. Neurology. 2006;67(11):2060–2.PubMedCrossRef Grimm SA, Yahalom J, Abrey LE, et al. Retinopathy in survivors of primary central nervous system lymphoma. Neurology. 2006;67(11):2060–2.PubMedCrossRef
47.
go back to reference Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.PubMedCrossRef Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.PubMedCrossRef
48.
go back to reference Al-Mefty O, Topsakal C, Pravdenkova S, et al. Radiation-induced meningiomas: clinical, pathological, cytokinetic, and cytogenetic characteristics. J Neurosurg. 2004;100(6):1002–13.PubMedCrossRef Al-Mefty O, Topsakal C, Pravdenkova S, et al. Radiation-induced meningiomas: clinical, pathological, cytokinetic, and cytogenetic characteristics. J Neurosurg. 2004;100(6):1002–13.PubMedCrossRef
49.•
go back to reference El-Jawahri A, Podgurski LM, Eichler AF, et al. Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol 2010; 28(2):305–310.PubMedCrossRef El-Jawahri A, Podgurski LM, Eichler AF, et al. Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol 2010; 28(2):305–310.PubMedCrossRef
50.
go back to reference Kaal ECA, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16:593–600.PubMedCrossRef Kaal ECA, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16:593–600.PubMedCrossRef
Metadata
Title
Medical Management of Patients With Brain Tumors
Author
Amy A. Pruitt, MD
Publication date
01-08-2011
Publisher
Current Science Inc.
Published in
Current Treatment Options in Neurology / Issue 4/2011
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-011-0132-y

Other articles of this Issue 4/2011

Current Treatment Options in Neurology 4/2011 Go to the issue

Neuro-oncology (Neoplasms)

High-Grade Gliomas